U.S. Oil and Gas Stock News

We can readily understand why investors are attracted to unprofitable companies. For example, Century Therapeutics...

Insiders who acquired US$128.6k worth of Quoin Pharmaceuticals, Ltd.'s ( NASDAQ:QNRX ) stock at an average price of...

The United States market has remained flat over the past week but has seen a significant increase of 21% over the past year, with earnings projected to grow by 18% annually. In this context, identifying promising small-cap stocks with notable insider activity can offer unique opportunities for investors seeking to capitalize on potential growth within a dynamic market landscape.

The United States market has remained flat over the past week but has experienced a significant 21% rise over the last year, with earnings projected to grow by 18% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability, positioning themselves well to capitalize on future opportunities in a dynamic economic environment.

In the last week, the United States market has been flat, yet it has seen a 21% increase over the past year with earnings forecasted to grow by 18% annually. In this context of growth and stability, identifying stocks trading below their intrinsic value can present potential opportunities for investors looking to capitalize on undervalued assets.

Over the last 7 days, the United States market has remained flat, though it has risen 21% over the past year with earnings forecasted to grow by 18% annually. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.

In the last week, the United States market has been flat, yet it remains up 21% over the past year with earnings forecasted to grow by 18% annually. In this environment, dividend stocks can offer a compelling opportunity for investors seeking steady income and potential capital appreciation.

Investors who take an interest in Greenfire Resources Ltd. ( NYSE:GFR ) should definitely note that the Independent...

With the business potentially at an important milestone, we thought we'd take a closer look at NRx Pharmaceuticals...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Despite the fact that American Coastal Insurance Corporation's (NASDAQ:ACIC) value has dropped 12% in the last week...

Crown Castle stock has fallen sharply over the past five years, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a discount to fundamentals, setting up a clear valuation debate after a difficult stretch for investors. Crown Castle's share price has declined 49.7% over the past five years, which means anyone who bought and held through this period has seen a substantial capital loss that now frames how attractive...

Eos Energy Enterprises secured a contract with the U.S. Department of War to deploy its American-made Z3 zinc-based long-duration energy storage technology. The project will support the Golden Dome for America national defense initiative focused on grid resilience and critical infrastructure. The agreement places Eos technology within U.S. defense and energy supply chains under a government-backed program. Eos Energy Enterprises, listed as NasdaqCM:EOSE, is moving into a new arena with this...

Columbia Threadneedle, part of Ameriprise Financial, has launched new actively managed ETFs focused on premium income and derivative income strategies. Johnson Stivender Wealth Advisors, a large advisory team previously at Raymond James, has joined the Ameriprise Financial platform. Ameriprise Financial (NYSE:AMP) is adding fresh product options and more advisor capacity at the same time, giving investors and clients additional ways to access its platform. The stock recently closed at...

FDA accepts BioMarin Pharmaceutical's supplemental New Drug Application for VOXZOGO for children with achondroplasia. Submission is based on extensive long-term safety and efficacy data from VOXZOGO treatment. The filing aims to convert VOXZOGO's existing authorization into full approval and address a major post marketing requirement. For BioMarin Pharmaceutical (NasdaqGS:BMRN), the FDA's acceptance of the VOXZOGO sNDA centers attention on its rare disease focus and its role in...

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) value has fallen 11% in the last week, but insiders who sold US$2.8m worth...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Cars.com Inc. ( NYSE:CARS ), is not the largest company out there, but it received a lot of attention from a...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Chemours stock has delivered a strong 51.1% gain year to date, yet its valuation checks still suggest the shares lean cheap rather than stretched after that run. Year to date, Chemours is up 51.1%, which puts recent weakness into context for investors weighing whether the move has already priced in the good news. Expectations around how Chemours can convert demand trends in its end markets into durable cash flows, while managing environmental and regulatory risks linked to its operations,...

UWM Holdings (UWMC) is back in focus after losing its bid to acquire Two Harbors Investment, as shareholders of Two Harbors approved a competing all cash offer from CrossCountry Mortgage. See our latest analysis for UWM Holdings. UWM Holdings’ recent setback on the Two Harbors deal comes after a sharp reset in sentiment, with the stock’s 30 day share price return down 13.6% and the year to date share price return down 54%, while the 1 year total shareholder return has declined 46.3%. This...

On July 7, 2026, activist investor Reference Equity released a letter and presentation to CBIZ’s Board, urging the company to halt share repurchases, resume its acquisition program, and raise equity capital to reposition the business for future growth. This intervention puts CBIZ’s capital allocation under the spotlight, questioning whether buybacks or renewed deal-making are better aligned with its growth ambitions. We’ll now examine how Reference Equity’s push to suspend buybacks and...

GE HealthCare Technologies has had a difficult year so far, with the stock down 23.7% year to date, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a discount. Recent headlines ranging from a prostate cancer research collaboration with Mayo Clinic to securities law investigations frame a valuation story that sits between long term potential in precision oncology and heightened risk perception. The share price has...

Skyworks Solutions has seen its share price fall about 65.6% over the past five years, yet current valuation checks suggest the stock now leans cheap relative to its estimated intrinsic value and earnings multiples. With a Discounted Cash Flow (DCF) estimate pointing to roughly 14.5% upside and market-based multiples also screening as undervalued, the key tension is whether this discount reflects opportunity or persistent concern about the business outlook. The share price decline of about...